Neogenomics Inc (NASDAQ: NEO)

Sector: Healthcare Industry: Diagnostics & Research CIK: 0001077183
P/B 1.82
P/E -13.47
P/S 2.15
Market Cap 1.53 Bn
ROIC (Qtr) -9.88
Div Yield % 0.00
Rev 1y % (Qtr) 11.90
Total Debt (Qtr) 410.31 Mn
Debt/Equity (Qtr) 0.49

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 164.12M provide 36.41x coverage of short-term debt 4.51M, demonstrating strong liquidity position and minimal refinancing risk.
  • Tangible assets of 556.27M provide exceptional 352.97x coverage of deferred revenue 1.58M, showing strong service capability backing.
  • Strong free cash flow of (17.05M) provides 2.64x coverage of acquisition spending (6.45M), indicating disciplined M&A strategy.
  • Operating cash flow of 13.69M provides strong 8.68x coverage of deferred revenue 1.58M, indicating service delivery capability.
  • Tangible assets of 556.27M provide robust 7.86x coverage of other current liabilities 70.75M, indicating strong asset backing.

Cons

  • Operating cash flow of 13.69M barely covers its investment activities of (11.50M), with a coverage ratio of -1.19, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (11.50M) provide weak support for R&D spending of 35.87M, which is -0.32x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Cash reserves of 164.12M provide limited coverage of acquisition spending of (6.45M), which is -25.43x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • High receivables of 155.30M relative to inventory of 28.46M (5.46 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.
  • The company's operating cash flow of 13.69M shows concerning coverage of stock compensation expenses of 41.60M, with a 0.33 ratio indicating potential earnings quality issues.

Peer Comparison

Companies in the Diagnostics & Research
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 216.83 Bn 33.00 4.96 35.68 Bn
2 DHR Danaher Corp /De/ 162.47 Bn 46.38 6.69 16.86 Bn
3 IDXX Idexx Laboratories Inc /De 56.88 Bn 55.36 13.65 1.09 Bn
4 A Agilent Technologies, Inc. 39.82 Bn 32.64 5.87 3.41 Bn
5 IQV Iqvia Holdings Inc. 38.85 Bn 30.28 2.44 15.19 Bn
6 NTRA Natera, Inc. 31.32 Bn -101.29 14.80 0.18 Bn
7 MTD Mettler Toledo International Inc/ 28.99 Bn 34.68 7.35 2.21 Bn
8 WAT Waters Corp /De/ 22.92 Bn 35.32 7.38 1.49 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 1.30 2.69
EV to Cash from Ops. 130.41 18.14
EV to Debt 4.35 52.51
EV to EBIT -16.34 19.22
EV to EBITDA -40.29 4.35
EV to Free Cash Flow [EV/FCF] -104.70 2.84
EV to Market Cap 1.17 1.52
EV to Revenue 2.52 4.79
Price to Book Value [P/B] 1.82 1.34
Price to Earnings [P/E] -13.47 22.02

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -1.96
Dividend Payout Ratio % 0.00 2.83
Dividend per Basic Share 0.00 0.19
FCF Dividend Payout Ratio % 0.00 1.92
Interest Coverage -22.86 -126.58

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 15.84 -31.50
Cash and Equivalents Growth (1y) % -54.66 21.37
Dividend Growth (1y) % 0.00 0.24
EBIAT Growth (1y) % -52.62 -55.24
EBITDA Growth (1y) % -336.02 -447.96
EBIT Growth (1y) % -49.28 -40.50
EBT Growth (1y) % -42.79 -70.94
EPS Growth (1y) % -44.26 -70.02
FCF Growth (1y) % 20.75 56.33
Gross Profit Growth (1y) % 9.90 185.11

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.52 0.56
Cash Payout Ratio 0.00 0.01
Cash Ratio 1.68 1.21
Current Ratio 3.91 2.64
Debt to Equity Ratio 0.49 -0.80
Interest Cover Ratio -22.86 -126.58
Times Interest Earned -22.86 -126.58

Profitability

Metric Value Industry Percentile
EBITDA Margin % -4.60 -129.91
EBIT Margin % -15.40 -156.71
EBT Margin % -16.07 -162.23
Gross Margin % 43.50 47.70
Net Profit Margin % -16.00 -189.30